The global helicobacter pylori diagnostics market size was estimated at USD 698.44 million in 2024 and is projected to reach USD 966.19 million by 2030, growing at a CAGR of 5.87% from 2025 to 2030. The market growth is largely driven by the increasing risk of gastrointestinal disorders, including gastritis, gastric ulcers, and stomach cancer, which has amplified the need for early and accurate diagnosis of Helicobacter pylori (H. pylori) infections.
Additionally, the growing geriatric population and the rising adoption of non-invasive diagnostic techniques are expected to further fuel market expansion. For instance, according to the National Library of Medicine, approximately 10% of individuals infected with H. pylori develop a peptic ulcer, while 1 to 3% may develop gastric adenocarcinoma, underscoring the importance of timely diagnosis and intervention.
Helicobacter pylori, a bacterium strongly associated with chronic gastritis, peptic ulcer disease, and gastric cancer, continues to drive innovation in diagnostic and therapeutic solutions. Recent advancements have particularly emerged in the field of nanotechnology, offering potential alternatives to traditional invasive procedures like endoscopy. Among these innovations, biosensors capable of detecting H. pylori-specific antigens or antibodies have gained significant attention. These biosensors utilize technologies such as piezoelectric, thermal, and sensor arrays to deliver highly accurate results, providing a less invasive and more cost-effective diagnostic approach compared to conventional methods such as PCR tests and immunoassays.
Key Market Trends Insights:
• In 2024, the North America Helicobacter pylori diagnostics market emerged as the largest regional market, accounting for a revenue share of 47.97%. The region’s dominance can be attributed to well-established healthcare infrastructure, increasing awareness about gastrointestinal disorders, and widespread adoption of advanced diagnostic solutions. The U.S. market in particular is witnessing steady growth, driven by rising prevalence of H. pylori infections and strong healthcare investment.
• When analyzed by type, the reagents segment led the market with a share of 44.47% in 2024, reflecting the critical role of diagnostic reagents in enabling accurate detection of H. pylori infections. Reagents are essential for various testing procedures, including immunoassays and PCR-based methods, making them a key contributor to the overall market revenue.
• Considering end use, the hospitals segment dominated the H. pylori diagnostics market in 2024, capturing 44.64% of the market share. Hospitals remain primary centers for diagnostic testing due to their advanced laboratory facilities, high patient volume, and capacity to perform a wide range of diagnostic procedures.
• By technology method, the immunoassays segment led the market in 2024 with a revenue share of 43.49%. Immunoassays are preferred for their accuracy, efficiency, and relatively non-invasive nature, making them widely adopted for detecting H. pylori-specific antigens or antibodies in clinical settings.
Order a free sample PDF of the Helicobacter Pylori Diagnostics Market Intelligence Study, published by Grand View Research.
Market Size Forecast:
• 2024 Market Size: USD 698.44 Million
• 2030 Projected Market Size: USD 966.19 Million
• CAGR (2025-2030): 5.87%
• North America: Largest market in 2024
Key Companies Market Share Insights:
Some of the key players in the Helicobacter pylori diagnostics market include Thermo Fisher Scientific, Biohit Oyj, Quest Diagnostics Incorporated, Meridian Bioscience, Bio-Rad Laboratories, Alpha Laboratories Ltd, F. Hoffmann-La Roche Ltd, Coris BioConcept, Certest Biotec, and Epitope Diagnostics, Inc. These companies are actively implementing various strategic initiatives to enhance their market presence and strengthen their competitive position.
Among the primary strategies employed are new product development, aimed at introducing innovative and more efficient diagnostic solutions to meet the evolving needs of healthcare providers and patients. Additionally, collaborations and partnerships are being pursued to expand technological capabilities, access new markets, and leverage combined expertise for more effective and comprehensive H. pylori diagnostic solutions. These efforts collectively help these players consolidate their market share and drive growth in a competitive landscape.
Key Players
• Thermo Fisher Scientific
• Biohit Oyj
• Quest Diagnostics Incorporated
• Meridian Bioscience
• Bio-Rad Laboratories
• Alpha Laboratories Ltd
• F. Hoffmann-La Roche Ltd
• Coris BioConcept
• Certest Biotec
• Epitope Diagnostics, Inc.
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion:
The global Helicobacter pylori diagnostics market is experiencing significant growth, driven by the increasing prevalence of gastrointestinal disorders such as gastritis, gastric ulcers, and stomach cancer. This rise in cases has heightened the demand for early and accurate detection of H. pylori infections. Advancements in diagnostic technologies, including non-invasive methods like urea breath tests and stool antigen tests, are enhancing detection accuracy and patient comfort. Additionally, the growing adoption of molecular diagnostics and point-of-care testing is expected to further propel market expansion.
